Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. freshman Good
|
New words:
acceleration, andreatta, aseptic, broke, Celgene, coli, counsel, disagreed, emphasize, explanatory, fielded, global, ground, hearing, Houston, incidence, instruct, LG, mBC, molecular, myelodysplastic, partner, Pension, Postretirement, Revlimid, RHI, robert, Singapore, small, solid, Torisel, Valtropin, withdrew
Removed:
ASCO, began, candidate, CEO, CFO, closing, declining, destroyed, Eastern, enrichment, entitled, fixed, improvement, individual, issuing, Kourosh, minimal, nomination, operation, Pennsylvania, pipeline, pool, predominantly, present, prompt, purported, RCC, reduction, shipment, sustainable, theory, transit, turn, twelve, unjust, upfront, validation, version
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 15.1 Letter Regarding Unaudited Interim Financial Information
- 31.1 Certification of Chief Executive Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 31.2 Certification of Chief Financial Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 32.1 Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
Related press release
Genentech similar filings
Filing view
External links